Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Gold

Showing results (591-600 of 596) with videos related to

Pageof 60
Sort By:
You have reached the last page of results.This site can display upto 596 results.
Seminars in Fetal & Neonatal Medicine|March 14, 2017
Classification of causes and associated conditions for stillbirths and neonatal deaths, Vicki Flenady, Aleena M Wojcieszek, et al.
JCO Precision Oncology|April 22, 2026
Temsirolimus in Patients With Solid Tumors With <i>PIK3CA</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyEvan Pisick, Michael Rothe, Elizabeth Garrett-Mayer, et al.
JCO Precision Oncology|October 16, 2025
Olaparib in Patients With Solid Tumors With <i>BRCA1/2</i> Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) StudyTareq Al Baghdadi, Michael Rothe, Pam K Mangat, et al.
Oncology (Williston Park, N.Y.)|April 27, 2023
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal AdenocarcinomaDaniel Vt Catenacci, Yoon-Koo Kang, Hope E Uronis, et al.
Frontiers in Environmental Science|July 21, 2023
Longitudinal stream synoptic monitoring tracks chemicals along watershed continuums: a typology of trendsSujay S Kaushal, Carly M Maas, Paul M Mayer, et al.
The Lancet. Oncology|July 13, 2020
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trialDaniel V T Catenacci, Yoon-Koo Kang, Haeseong Park, et al.
Pageof 60

Showing results (591-600 of 596) with videos related to

Sort By:
Pageof 60
You have reached the last page of results.This site can display upto 596 results.
Seminars in Fetal & Neonatal Medicine|March 14, 2017
Classification of causes and associated conditions for stillbirths and neonatal deaths, Vicki Flenady, Aleena M Wojcieszek, et al.
JCO Precision Oncology|April 22, 2026
Temsirolimus in Patients With Solid Tumors With <i>PIK3CA</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyEvan Pisick, Michael Rothe, Elizabeth Garrett-Mayer, et al.
JCO Precision Oncology|October 16, 2025
Olaparib in Patients With Solid Tumors With <i>BRCA1/2</i> Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) StudyTareq Al Baghdadi, Michael Rothe, Pam K Mangat, et al.
Oncology (Williston Park, N.Y.)|April 27, 2023
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal AdenocarcinomaDaniel Vt Catenacci, Yoon-Koo Kang, Hope E Uronis, et al.
Frontiers in Environmental Science|July 21, 2023
Longitudinal stream synoptic monitoring tracks chemicals along watershed continuums: a typology of trendsSujay S Kaushal, Carly M Maas, Paul M Mayer, et al.
The Lancet. Oncology|July 13, 2020
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trialDaniel V T Catenacci, Yoon-Koo Kang, Haeseong Park, et al.
Pageof 60